1.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed 4. Lyon, IARC, 2008.
2.
Alsagaby SA, Brennan P, Pepper C: Key molecular drivers of chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 2016;16:593-606.
3.
Delgado J, Villamor N, López-Guillermo A, Campo E: Genetic evolution in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2016;29:67-78.
4.
González-Gascón Y, Marín I, Hernández-Sánchez M, Rodríguez-Vicente AE, Sanzo C, Aventín A, Puiggros A, Collado R, Heras C, Muñoz C, Delgado J, Ortega M, González MT, Marugán I, de la Fuente I, Recio I, Bosch F, Espinet B, González M, Hernández-Rivas JM, Hernández JÁ: A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia. Hematol Oncol 2016;34:84-92.
5.
Rossi D, Gerber B, Stüssi G: Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia. Leuk Lymphoma 2016;3:1-13.
6.
Yi S, Li Z, Zou D, An G, Cui R, Zhong S, Li H, Xiong W, Li C, Chen W, Liu W, Lv R, Yu Z, Wang H, Xu Y, Zhou K, Ru K, Wang J, Cheng T, Qiu L: Intratumoral genetic heterogeneity and number of cytogenetic aberrations provide additional prognostic significance in chronic lymphocytic leukemia. Genet Med 2017;19:182-191.
7.
Landau DA, Carter SL, Getz G, Wu CJ: Clonal evolution in hematological malignancies and therapeutic implications. Leukemia 2014;28:34-43.
8.
Weigert O, Weinstock DM: The evolving contribution of hematopoietic progenitor cells to lymphomagenesis. Blood 2012;120:2553-2561.
9.
Alpatov R, Carstens B, Harding K, Jarrett C, Balakhani S, Lincoln J, Brzeskiewicz P, Guo Y, Ohene-Mobley A, LeRoux J, McDaniel V, Meltesen L, Minka D, Patel M, Manavi C, Swisshelm K: Rare double-hit with two translocations involving IGH both, with BCL2 and BCL3, in a monoclonal B-cell lymphoma/leukemia. Mol Cytogenet 2015;8:101.
10.
Baseggio L, Geay MO, Gazzo S, Berger F, Traverse-Glehen A, Ffrench M, Hayette S, Callet-Bauchu E, Verney A, Morel D, Jallades L, Magaud JP, Salles G, Felman P: In non-follicular lymphoproliferative disorders, IGH/BCL2-fusion is not restricted to chronic lymphocytic leukaemia. Br J Haematol 2012;158:489-498.
11.
Lau LC, Lim P, Lim YC, Teng LM, Lim TH, Lim LC, Tan SY, Lim ST, Sanger WG, Tien SL: Occurrence of trisomy 12, t(14;18)(q32;q21), and t(8;14)(q24.1;q11.2) in a patient with B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet 2008;185:95-101.
12.
Tang G, Banks HE, Sargent RL, Medeiros LJ, Abruzzo LV: Chronic lymphocytic leukemia with t(14;18)(q32;q21). Hum Pathol 2013;44:598-605.
13.
Ortíz-Maldonado V, Mozas P, Delgado J: The biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemia. Ther Adv Hematol 2016;7:321-329.
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or...
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.